INTRODUCTION
============

Obesity is caused by the imbalance of energy metabolism. But it is not clear whether higher intake or lower consumption is more important. Consumed energy can be roughly divided into activity energy expenditure and resting energy expenditure (REE). Furthermore, REE can be subdivided into obligatory energy expenditure, which is absolutely necessary for life conservation, and adaptive thermogenesis, which is induced by cold exposure or food intake. In addition, REE can deviate by about 25% depending on an individual's metabolism [@B001],[@B002]. Also, since REE takes up the most part of the total energy consumption, even minor differences of REE can manifest as considerable metabolic changes in the long-term, which greatly affects weight control. Thus, reduced REE may be the greatest risk factor of obesity [@B003].

People with reduced REE easily become obese, even if they eat less than others do. Studies seeking to determine a genetic basis continue to be carried out. To examine the correlation between obesity and heredity, in the early stage, studies on twins, adoptees and genealogy had been carried out. The collective results to date indicate that 40% to 70% of the differences of the obesity-related phenotypes are affected by heredity [@B004]. Recently, with the development of molecular biological technology on genes, studies aimed at determining what genes determine energy metabolism are being actively carried out.

The occurrence of gene mutants in a single base pair with a frequency of over 1%, which is relatively common, is called gene polymorphism or single nucleotide polymorphism (SNP). Forty SNPs related to obesity have been identified in various studies [@B004]. Among them, beta 3 adrenergic receptor (ADRB3), G protein beta 3 (GNB3) and angiotensin I converting enzyme (ACE) are important genes that control REE.

Korean red ginseng (KRG) is steamed and dried ginseng [@B005]. KRG is effective for male impotence, prevention of relapse of stomach cancer, and possible treatment of human immunodeficiency virus-1 infection [@B006]-[@B008]. Also, KRG or ginseng has been proven to be very effective for improving obesity and abnormal metabolism in animal studies and clinical studies [@B009]-[@B012]. These effects of KRG and ginseng on the treatment of obesity can be thought to be greater in the obesity caused by reduced energy metabolism. However, there have been no pharmacogenomic studies using ginseng or KRG applied to obesity and no studies related to genotype.

Therefore, this study tried to examine the effects of KRG on obese women by administrating 6 g of powdered KRG three times a day for 8 weeks and to confirm that the effects of KRG on the improvement of obesity differed depending on the polymorphism of a gene(s) related to energy metabolism. It was assumed that if a mutation takes place in the energy metabolism-related ADRB3, GNB3, and ACE genes, the risk of the occurrence of obesity would increases and that the effects of KRG on the improvement of obesity that stimulates energy metabolism would increase.

MATERIALS AND METHODS
=====================

Study plan
----------

This clinical study was a randomized, double-blind, placebo-controlled, single center clinical trial. It was carried out on 50 obese females in the Dongguk University Ilsan Oriental Hospital. Approval for the trial was granted by the Hospital's Institutional Review Board (approval no. SR-15).

Subject recruitment
-------------------

Through posters in the hospital and advertisements on local daily news, from October 2010 through February 2011, 69 volunteers were recruited and 50 persons were selected as the final subjects based on the following criteria for inclusion and exclusion ([Table 1](#T001){ref-type="table"}).

###### 

Study selection criteria

  ---------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Inclusion criteria                                         Exclusion criteria
                                                             
  Subjects aged of 18-65 yr                                  Subjects with significant history or current presence of cardiovascular disease, hepatic and renal
  BMI ≥25 kg/m^2^                                              dysfunction, cancer
  Weight stable individuals (≤±3 kg) in the preceding 3 mo      ALT, AST \>2.5 times of normal range
  Sedentary individuals                                         Creatinine \>2.0 mg/dL
  Otherwise healthy nonsmokers                                  Clinically significant abnormal electrocardiogram
  Subjects signed informed consent forms                     Patient on drugs that could have interfered with the conduct of the study
                                                             Known allergy or sensitivity to any of the medication
                                                             Pregnant women
  ---------------------------------------------------------- ----------------------------------------------------------------------------------------------------

BMI, body mass index; ALT, aminotransferase; AST, aspartate aminotransferase.

Random assignment and double blind test
---------------------------------------

A randomization code was produced by a statistician, using the SAS system based on the block assignment method with a block size of 4. This randomization code was provided only to the persons in charge of the study in Korea Ginseng Corporation, and was blinded for the remainder of people concerned with the study until the termination of the study. In the order of the randomization code, the recruited patients were randomly assigned to the KRG group or the placebo group. KRG and placebo with randomization code on them were provided from Korea Ginseng Corporation and were distributed to the patients by the administrative pharmacist. To maintain the double blinding, the test medicine and the placebo were packed in the same shape capsule. To check the appropriateness of the blind test for the subjects, after the study, a self-questionnaire was carried out to ask whether they have taken real KRG or placebo.

Drug administration
-------------------

The subjects assigned to the KRG group were required to take 12 capsules of 500 mg KRG (Jeong Gwan Jang; Korea Ginseng Corporation, Daejeon, Korea) for a total of 6 g extract, three times a day, while those assigned to the placebo group took a corn starch capsules of the same quantity and shape placebo. Drugs for 2 wk were provided at a single visit, and subjects were asked to revisit every second week for a total of 8 wk. The subjects were required to return leftover drugs in the next visit, through which their compliance to the administration was checked. Over 80% compliance was taken as the target of per protocol (PP) analysis. During the study period, the subjects were not restricted with their caloric intake and were allowed to eat meals as usual. However, an extreme diet that might affect the results such as binge eating or fasting was prohibited, and subjects were asked to maintain their normal activities, but were prohibited from beginning new exercise.

Effectiveness and safety evaluation item
----------------------------------------

Before drug administration, blood pressure (BP), height, weight, waist circumference (WC), waist-hip ratio (WHR), total fat mass (FM), percentage of body fat (BF%), resting metabolic rate (RMR), basal body temperature, daily food intake (FI), blood test (serum lipid, liver function, and renal function), and a gene examination were conducted. As well, a questionnaire concerning the oriental medical obesity pattern differentiation and the Korean-style questionnaire on the quality of life (KOQOL) were completed by each subject. Each subject was required to revisit once every second week. At each visit, their BP, weight, WC, WHR, basal body temperature, and daily food intake were checked. Additionally, at weeks 4 and 8, FM, BF%, and RMR were checked. At the end of the study at week 8, a blood test was conducted and each subject again completed the KOQOL questionnaire.

### Blood pressure, heart rate

BP and pulse at the radial artery were measured after a more than 10 min rest upon every visit with a mercury sphygmomanometer while each subject was seated.

### Anthropometric assessment

The height of each subject was measured once to the nearest 0.1 cm at the first visit. Weight was measured to the nearest 0.1 kg unit every second week while each subject was minimally clothed. WC was measured with each subject in an upright posture at the mid-section between the lowest costal margin and the iliac crest (3 cm up of the anterior superior iliac spine), according to World Health Organization methodology. WC measurements were made by the same skilled measurer to verify intra-examiner-variability and the mean of three consecutive measurements was determined without pressing the skin at the end of exhalation using the same tapeline. For body mass index (BMI, kg/m^2^), subjects were measured during each visit.

### Bioelectrical impedance

Bioelectrical impedance was determined using Inbody 3.0 (Biospace, Seoul, Korea). Measurements were carried out at the first visit and at weeks 4 and 8. As the evaluation parameters, total fat and BF% were chosen.

### Resting metabolic rate measurement

Using gas exchange measurement-type portable indirect calorimetry (MedGem; Healthtech, Golden, CO, USA), RMR was measured at the first visit and at weeks 4 and 8. All measurements were done after a 30 min rest.

### Blood test

To exclude liver, kidney, and metabolic diseases before the start of clinical trials, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urine nitrogen (BUN), creatinine, glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides were measured. ALT and AST results over 2.5 times the normal upper limit and creatinine value over 2.0 mg/dL were excluded and blood testing was carried out at week 8. Glucose and blood lipid tests were measured through an analysis of blood gathered after a 12- hour fast.

### Basal body temperature

A mercury thermometer was distributed to the subjects, who were required to measure their armpit temperature for 10 min immediately after awakening. Each subject was phoned to enquire of the first measurement on the morning of their first clinic visit. Each reading was recorded by the skilled clinical research nurse. Temperature was measured again and recorded at the time of the first visit.

### Daily food intake

The amount of food intake the day preceding each clinic visit was checked by a 24-hour dietary recall method using the Computer Aided Nutritional analysis program, version 3.0, developed by The Korean Nutrition Society.

### Gene analysis

DNA was separated from the peripheral venous blood of each subject by a previously described method [@B013]. One milliliter of each blood sample was added to a 2 mL micro-tube and 25 μL of a solution of 1 mL NP-40 in TKM1 buffer was added to dissolve the blood cells. Following washing in TKM1 buffer and solution containing 160 μL TKM2 buffer and 10 μL 10% sodium dodecyl sulfate was added. Each sample was heated at 55℃ degree for 10 min and 6 M NaCl was added to precipitate protein. DNA was precipitated using 100% ethanol and washed with 70% ethanol. The extracted DNA was stored in Tris-EDTA buffer. Polymerase chain reaction (PCR) was conducted to amplify the GNB3, ADRB3, and ACE genes.

For GNB3 PCR, 30 ng of extracted DNA received SNP sense primer (5'-TGACCCACTTGCCACCCGTGC- 3') and SNP anti-sense primer (5'-GCAGCAGCCAGGGCTGGC- 3'), DNA polymerase, and PCR reaction buffer. The DNA was denaturated at 94℃ for 10 min and PCR was carried out using the following conditions: 35 cycles at 94℃ for 60 s, 60℃ for 45 s, 72℃ for 60 s, and, finally, 72℃ for 10 min. Electrophoresis was done for 30 min using a dye crack reactor and the presence of an amplified band was ascertained. Since the T allele is 268 bp and the C allele is 152 and 116 bps, if a band appeared at 152 and 116 bps, it was classified as C/C type; if it appeared at 152, 116, and 268 bps, it was classified as the C/T type; and if it appeared at 268 bp, it was classified as the T/T type.

For ADRB3 PCR, electrophoresis was performed for 30 min mixing with sense primer (5'-CGCCCAATACCGCCAACAC- 3') and anti-sense primer (5'-CCACCAGGAGTCCCATCACC- 3') and DNA polymerase PCR buffer with 30 ng of the extracted DNA. Following PCR as described above, the product was digested with Mval restriction enzyme. If, upon electrophoresis, an amplified band was observed at 99 bp, it was classified as the Trp64/Trp allele, while presence of a band at 161 bp indicated an Arg64/Arg allele; if the band appeared at 99 bp, it was classifi ed into Trp64/Trp type; if it appeared at 99 and 161 bps, it was classified as Trp64/ Argg type; if it appeared at 161 bp, it was classified as Arg64/Arg type.

For ACE, using the separated DNA and ACE primer set (SNP sense primer: 5'-CTGGACACCACTCCCATCCTTTCT- 3'; antisense primer: 5'-GATGTGGCCATCACATTCGTCAGA- 3'), PCR was carried out. Following the 30 min electrophoresis, appearance of a band was ascertained. The D allele is 235 bp while for the I allele is 153 and 523 bp. Therefore, if the band appeared in 245 bp, it was classified into the D/D type; if it appeared at 235, 153, and 523 bp, it was classified as the D/I type; and if it appeared at 153 and 523 bp, it was classified as the I/I type.

### Korean-style questionnaire on the quality of life evaluation

Subjects completed the KOQOL questionnaire developed in 2003 at baseline and the end of the study [@B014]. The KOQOL evaluation questionnaire consists of 15 questions in six areas (mental and social health, physical health, job and domestic duty, daily life, sexual relations, and food), which are known to be relatively simple but highly reliable and accurate.

Statistical analyses
--------------------

All statistical analyses were carried out using SAS ver. 9.1 (SAS Inc., Cary, NC, USA). Data represent mean±standard deviation. Statistical analysis was made by PP analysis. Student's *t*-test was carried out for the comparison of KRG and placebo group. A paired *t*-test was carried out for the comparison of values before and after the study. A *p*-value of less than 0.05 was considered statistically significant.

RESULTS
=======

Research process
----------------

Sixty nine volunteers were recruited. Of these, 12 could not be contacted and seven were excluded upon screening. The remaining 50 subjects were randomly processed, and 26 subjects were assigned to the KRG group and 24 subjects to the placebo group. During the 8-week trial, 4 subjects were dropped out from KRG group and one was dropped out from the placebo group. Twenty two subjects in the KRG group and 23 in the placebo group completed the study ([Fig. 1](#F001){ref-type="fig"}). Compliance with the study regimen by the subjects was 80%, so 45 subjects were selected for PP analysis.

![Flow chart of participants disposition. KRG, Korean red ginseng.](grosbr-36-176-g001){#F001}

Comparison of characteristics of both groups before administration
------------------------------------------------------------------

Waist-hip circumference ratio of the placebo group was significantly greater than that of the KRG group (*p*=0.0222), while ALT of the placebo group was significantly greater than that of KRG group (*p*=0.0154). No other significant differences were evident between KRG and placebo groups ([Table 2](#T002){ref-type="table"}).

###### 

Demographics of participants

  ----------- ----- ----------------- ----- ----------------- ---------------
  Variables   No.   Red ginseng       No.   Placebo           *p*-value^1)^
                                                              
  Age         22    40.91±9.65        23    46.48±9.79        0.0613
  Height      22    160.66±6.42       23    158.13±5.04       0.1467
  BW          22    73.85±8.64        23    72.7±10.65        0.6957
  BMI         22    28.62±2.68        23    28.99±3.25        0.6808
  RMR         22    1,624.09±217.2    23    1,628.7±390.77    0.9611
  WC          22    95.32±7.2         23    96.31±8.03        0.6659
  WHR         22    0.92±0.04         23    0.95±0.05         0.0222^\*^
  BF%         22    39.4±4.65         23    40.31±4.33        0.5030
  BFM         22    29.27±6.06        23    29.51±6.79        0.9011
  FI          22    1,836.77±603.67   23    1,939.48±397.08   0.5019
  BBT         22    36.59±0.38        23    36.5±0.26         0.3750
  KOQOL       22    38.82±5.72        23    35.04±8.36        0.0857
  BST         22    105.91±11.48      23    108.7±15.24       0.4936
  TG          22    119.95±55.18      22    136.59±98.33      0.4938
  HDL         22    53.27±10.39       22    51.32±11.32       0.5539
  T-Chol      22    190.09±35.38      23    195.04±34.02      0.6346
  BUN         22    12.65±3.2         23    12.07±2.96        0.5273
  Cr          22    0.66±0.1          23    0.66±0.09         0.9218
  AST         22    20.05±5.58        23    25.65±12.07       0.0526
  ALT         22    19.14±11.37       23    29.7±16.17        0.0154^\*^
  SBP         22    122.18±9.46       23    123.61±9.91       0.6241
  DBP         22    77.23±7.32        23    77.61±7.4         0.8629
  PR          22    78.27±11.55       23    74.43±6.69        0.1841
  RR          20    1.19±0.19         22    1.11±0.22         0.2620
  ----------- ----- ----------------- ----- ----------------- ---------------

Values are presented as mean±SD.

BW, body weight; BMI, body mass index; RMR, resting metabolic rate; WC, waist circumference; WHR, waist hip ratio; BF%, percentage of body fat; BFM, body fat mass; FI, food intake; BBT, basal body temperature; KOQOL, Korean obesity quality of life; BST, blood sugar test; TG, triglyceride; HDL, high density lipoprotein; T-Chol, total cholesterol; BUN, blood urine nitrogen; Cr, creatinine; AST, aspartate aminotransferase; ALT, aminotransferase; SBP, systolic blood pressure; DBP, diastolic blood pressure; PR, pulse rate; RR, RR interval.

^1)^ *p*-value derived from Student's *t*-test.

\* *p*\<0.05

Effects of Korean red ginseng on the improvement of obesity
-----------------------------------------------------------

After the trial, the weights of two subjects (9.09%) of the 22 in the KRG group were reduced over 5%, while none of the 23 placebo subjects displayed weight losses over 5%. The findings were not statistically significant (*p*=0.2333).

Notably, in the comparison between before and after the administration of KRG group, there were significant improvements of obesity in the items of body weight (*p*=0.0045), BMI (*p*=0.0352), WHR (*p*=0.0312), daily FI (*p*=0.0100), and KOQOL (*p*=0.004). However, in the comparison between KRG Group and placebo group only KOQOL was significantly different ([Table 3](#T003){ref-type="table"}).

###### 

Changes of parameters after intervention

  ----------- ------------- ---------------- --------------- ----- ---------------- ---------------
  Variables   Red ginseng   Placebo                                                 
                                                                                    
              No.           Mean±SD          *p*-value^1)^   No.   Mean±SD          *p*-value^2)^
                                                                                    
  ΔBW         22            -0.75±1.66       0.0445^\*^      23    -0.73±1.58       0.9603
  ΔBMI        22            -0.3±0.63        0.0352^\*^      23    -0.33±0.64       0.8745
  ΔRMR        22            55.45±253.22     0.3160          23    -4.35±231.77     0.4128
  ΔWC         22            -1±2.94          0.1239          23    -4.19±13.09      0.2661
  ΔWHR        22            0±0.01           0.0312^\*^      23    0±0.01           0.2217
  ΔBF%        22            -0.06±1.59       0.8527          23    -0.6±0.9         0.1684
  ΔBFM        22            -0.41±1.45       0.1946          23    -0.69±1.03       0.4678
  ΔFI         22            -386.73±640.88   0.0100^\*^      23    -288.04±400.86   0.5418
  ΔBBT        22            -0.13±0.46       0.2114          22    -0.15±0.44       0.8676
  ΔKOQOL      22            -5.18±5.79       0.0004^\*^      23    -0.91±5.91       0.0186^\*^
  ΔBST        22            -7.27±17.16      0.0600          23    -4.7±13.14       0.5735
  ΔTG         22            -10.45±76.11     0.5264          22    -25.18±75.62     0.5232
  ΔHDL        22            1.18±7.21        0.4505          22    2.14±9.67        0.7123
  ΔT-Chol     22            4.91±33.43       0.4986          23    -1.7±19.72       0.4278
  ΔSBP        22            -2.86±13.09      0.3164          23    -1.43±10.57      0.6883
  ΔDBP        22            -3.86±10.75      0.1068          23    -1.13±6.92       0.3142
  ΔPR         22            -1.05±12.2       0.6919          23    -2.13±9.36       0.7388
  ΔRR         19            -0.01±0.2        0.8824          22    0.05±0.23        0.4472
  ----------- ------------- ---------------- --------------- ----- ---------------- ---------------

BW, body weight; BMI, body mass index; RMR, resting metabolic rate; WC, waist circumference; WHR, waist hip ratio; BF%, percentage of body fat; BFM, body fat mass; FI, food intake; BBT, basal body temperature; KOQOL, Korean obesity quality of life; BST, blood sugar test; TG, triglyceride; HDL, high density lipoprotein; T-Chol, total cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; PR, pulse rate; RR, RR interval.

^1)^ *p*-value derived from paired *t*-test between pre and post.

^2)^ *p*-value derived from Student's *t*-test between red ginseng group and placebo group.

^\*^*p*\<0.05.

Comparison of obesity indices by gene polymorphism type
-------------------------------------------------------

For 48 persons on whom gene analysis had been made among the total of 50 persons, to see if obesity indices before drug administration differs depending on gene polymorphism, they were divided into one with and without gene mutation and compared and analyzed.

### G protein beta 3

Six subjects were indicated to lack gene mutation (i.e., CC type), while 42 displayed a single mutation (39 CT type and three TT type). In the comparison between the two groups, subjects with gene mutation (CT+TT) displayed significantly higher BMI (*p*=0.027), BF% (*p*=0.001) and systolic BP (*p*=0.034) than subjects with no gene mutation (CC) ([Table 4](#T004){ref-type="table"}).

###### 

Comparison of baseline characteristics by GNB3 polymorphism

  -------- ----- ----------------- --------------- ----------------- -----------
           CC    CT + TT           *p*-value^1)^                     
                                                                     
           No.   Mean±SD           No.             Mean±SD           
                                                                     
  BW       6     67.683±7.44       42              73.917±9.90       0.146
  BMI      6     26.383±1.89       42              29.217±2.94       0.027^\*^
  RMR      6     1,651.67±239.95   42              1,625.00±315.67   0.844
  WC       6     91.13±5.96        42              96.61±7.89        0.110
  WHR      6     0.9083±0.03       42              0.9424±0.05       0.122
  BF%      6     37.217±1.38       42              40.557±4.55       0.001^\*^
  BFM      6     25.167±2.49       42              30.176±6.55       0.072
  FI       6     1,942.67±679.08   42              1,856.55±484.16   0.700
  BBT      6     36.483±0.51       42              36.550±0.29       0.766
  KOQOL    6     37.83±10.61       42              36.74±6.67        0.729
  BST      6     100.50±5.32       42              108.43±13.73      0.171
  TG       6     81.80±32.62       42              130.36±77.31      0.175
  HDL      5     53.60±9.99        42              52.12±10.77       0.771
  T-Chol   5     176.83±26.98      42              195.81±34.73      0.207
  SBP      6     118.17±3.87       42              123.33±10.39      0.034^\*^
  DBP      6     78.00±3.41        42              77.24±7.86        0.686
  -------- ----- ----------------- --------------- ----------------- -----------

GNB3, G protein beta 3; BW, body weight; BMI, body mass index; RMR, resting metabolic rate; WC, waist circumference; WHR, waist hip ratio; BF%, percentage of body fat; BFM, body fat mass; FI, food intake; BBT, basal body temperature; KOQOL, Korean obesity quality of life; BST, blood sugar test; TG, triglyceride; HDL, high density lipoprotein; T-Chol, total cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.

^1)^ *p*-value derived from Student's *t*-test between CC group and CT+TT group.

^\*^ *p*\<0.05.

### Beta 3 adrenergic receptor

Thirty three subjects were classified as lacking ADRBr gene mutation (Trp64/Trp) while 15 subjects harbored a mutation (10 in Trp64/Arg and five in Arg64/Arg). In the comparison between the two groups, subjects with gene mutation displayed significantly lower HDL than subjects lacking gene mutation (*p*=0.012) ([Table 5](#T005){ref-type="table"}).

###### 

Comparison of baseline characteristics by ADRB3 polymorphism

  -------- ----------- --------------------- --------------- --------------- -----------
           Trp64/Trp   Trp64/Arg+Arg64/Arg   *p*-value^1)^                   
                                                                             
           No.         Mean±SD               No.             Mean±SD         
                                                                             
  BW       33          72.352±9.34           15              74.867±10.83    0.415
  BMI      33          28.570±2.70           15              29.507±2.70     0.316
  RMR      33          1,654.55±317.04       15              1,570.67±3.50   0.383
  WC       33          94.93±6.76            15              98.12±317.04    0.263
  WHR      33          0.9370±0.05           15              0.9407±278.81   0.816
  BF%      33          39.691±4.15           15              41.127±6.76     0.301
  BFM      33          28.870±6.00           15              31.047±9.72     0.279
  FI       33          1,810.79±541.01       15              1,991.67±0.05   0.254
  BBT      33          36.530±0.31           15              36.567±0.05     0.718
  KOQOL    33          36.24±7.75            15              38.27±4.15      0.368
  BST      33          107.61±14.02          15              107.07±4.96     0.897
  TG       33          116.66±47.47          15              143.40±6.00     0.260
  HDL      33          54.88±9.40            15              46.73±7.16      0.012^\*^
  T-Chol   33          191.94±35.62          15              196.73±541.01   0.658
  SBP      33          121.58±10.27          15              125.13±401.07   0.255
  DBP      33          77.21±7.43            15              77.60±0.31      0.869
  -------- ----------- --------------------- --------------- --------------- -----------

ADRB3, beta 3 adrenergic receptor; BW, body weight; BMI, body mass index; RMR, resting metabolic rate; WC, waist circumference; WHR, waist hip ratio; BF%, percentage of body fat; BFM, body fat mass; FI, food intake; BBT, basal body temperature; KOQOL, Korean obesity quality of life; BST, blood sugar test; TG, triglyceride; HDL, high density lipoprotein; T-Chol, total cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.

^1)^*p*-value derived from Student's *t*-test between Trp64/Trp group and Trp64/Arg + Arg64/Arg group.

^\*^*p*\<0.05.

### Angiotensin I converting enzyme

Sixteen subjects lacked gene mutation (II), while 32 subjects did (22 in ID and 10 in DD). There was no significant difference in the comparison between the two groups ([Table 6](#T006){ref-type="table"}).

###### 

Comparison of baseline characteristics by ACE polymorphism

  -------- ----- ----------------- --------------- ----------------- -------
           II    ID+DD             *p*-value^1)^                     
                                                                     
           No.   Mean±SD           No.             Mean±SD           
                                                                     
  BW       16    72.050±9.81       32              75.313±9.65       0.281
  BMI      16    28.541±2.81       32              29.506±3.25       0.293
  RMR      16    1,610.31±308.47   32              1,664.38±305.11   0.568
  WC       16    94.98±7.88        32              97.81±7.65        0.243
  WHR      16    0.9344±0.05       32              0.9456±0.05       0.471
  BF%      16    40.131±4.59       32              40.156±4.18       0.985
  BFM      16    29.128±6.69       32              30.394±5.87       0.524
  FI       16    1,817.53±525.77   32              1,966.88±458.11   0.339
  BBT      16    36.506±0.30       32              36.613±0.36       0.281
  KOQOL    16    36.88±7.17        32              36.88±7.29        1.000
  BST      16    106.34±12.02      32              109.63±15.50      0.423
  TG       16    121.48±86.50      32              132.38±47.71      0.643
  HDL      16    52.65±11.01       32              51.56±10.05       0.744
  T-Chol   16    190.59±35.64      32              199.13±31.45      0.421
  SBP      16    121.88±11.34      32              124.31±6.30       0.344
  DBP      16    77.41±7.03        32              77.19±8.42        0.925
  -------- ----- ----------------- --------------- ----------------- -------

ACE, angiotensin I converting enzyme; BW, body weight; BMI, body mass index; RMR, resting metabolic rate; WC, waist circumference; WHR, waist hip ratio; BF%, percentage of body fat; BFM, body fat mass; FI, food intake; BBT, basal body temperature; KOQOL, Korean obesity quality of life; BST, blood sugar test; TG, triglyceride; HDL, high density lipoprotein; T-Chol, total cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.

^1)^ *p*-value derived from Student's *t*-test between II group and II + DD group.

Effects of Korean red ginseng on the improvement of obesity by gene polymorphism type
-------------------------------------------------------------------------------------

The gene sample of one subject of the 22 in the KRG group who completed the clinical study was lost. So, the differences of obesity indices between before and after were analyzed for 21 subjects.

### G protein beta 3

Of the 21 subjects, three were CC type without mutation, 17 were CT type with homogenous mutation, and one was TT type with heterogenic mutation. As a result of analysis of obesity indices before and after the ad-ministration of KRG according to gene polymorphism type, BMI (*p*=0.0387) and KOQOL (*p*=0.0002) were associated with significant effects on the improvement of obesity in the CT type, while there was no significant effects in the CC type. Food intake was significantly reduced in the CC type (*p*=0.0100), and displayed a decreasing, but statistically insignificant, tendency in the CT type. Systolic BP was significantly increased in the CC type (*p*=0.0377), while it tended to be reduced in the CT type. WHR was significantly increased in the CT type (*p*=0.0144) ([Table 7](#T007){ref-type="table"}).

###### 

Changes of parameters after intervention by GNB3 genotype in Korean red ginseng group

  -------- ----------- ----------------- ----------------- ---------------
           Genotype    Pre               Post              *p*-value^1)^
                                                           
  BW       CC (N=3)    72.57±7.99        71.97±7.71        0.3479
           CT (N=17)   74.94±8.91        74.1±8.32         0.0630
           TT (N=1)    62.3±.            64±.              \-
  BMI      CC (N=3)    27.2±2.61         26.97±2.31        0.3688
           CT (N=17)   29.16±2.66        28.81±2.72        0.0387^\*^
           TT (N=1)    26.1±.            26.9±.            \-
  RMR      CC (N=3)    1,843.33±171.56   1,836.67±263.5    0.9340
           CT (N=17)   1,615.88±199.66   1,671.18±236.85   0.4332
           TT (N=1)    1280±             1430±.            \-
  WC       CC (N=3)    93.83±0.76        94.4±1.13         0.5803
           CT (N=17)   96.31±7.86        95.08±6.75        0.1221
           TT (N=1)    89±.              90.2±             \-
  WHR      CC (N=3)    0.9±0.03          0.9±0.04          0.4226
           CT (N=17)   0.92±0.05         0.93±0.05         0.0144^\*^
           TT (N=1)    0.94±.            0.94±.            \-
  BF%      CC (N=3)    36.33±1.45        36.33±2.78        1
           CT (N=17)   40.16±4.82        40.09±4.73        0.8618
           TT (N=1)    41.6±.            40.6±.            \-
  BFM      CC (N=3)    26.4±3.29         26.3±4.59         0.9067
           CT (N=17)   30.31±6.45        29.8±5.96         0.2051
           TT (N=1)    25.9±.            26±.              \-
  FI       CC (N=3)    2,431.33±389.71   1,545.33±544.58   0.0100^\*^
           CT (N=17)   1,782.41±587.51   1,475±344.17      0.0781
           TT (N=1)    991±.             1157±.            \-
  BBT      CC (N=3)    36.77±0.59        36.67±0.15        0.7418
           CT (N=17)   36.61±0.33        36.41±0.29        0.0549
           TT (N=1)    36±.              37±.              \-
  KOQOL    CC (N=3)    45.33±4.51        42.67±9.07        0.6813
           CT (N=17)   37.71±5.35        31.59±6.99        0.0002^\*^
           TT (N=1)    43±.              42±.              \-
  BST      CC (N=3)    100±6.56          91±13.53          0.5187
           CT (N=17)   105.82±10.54      101.06±12.05      0.2309
           TT (N=1)    133±.             90±.              \-
  TG       CC (N=3)    77±37.64          66.67±14.98       0.6221
           CT (N=17)   116.88±45.62      105.35±73.97      0.5295
           TT (N=1)    157±.             282±.             \-
  HDL      CC (N=3)    55.33±11.15       56.33±8.62        0.8600
           CT (N=17)   53.47±11.05       54.88±12.43       0.4362
           TT (N=1)    50±.              43±.              \-
  T-Chol   CC (N=3)    191.33±25.93      181±17.69         0.3191
           CT (N=17)   184.29±33.55      190.59±54.58      0.4866
           TT (N=1)    268±.             263±.             \-
  BUN      CC (N=3)    14.13±0.51        15.5±3.47         0.5120
           CT (N=17)   12.46±3.47        12.15±3.02        0.6652
           TT (N=1)    9.5±.             13.2±.            \-
  Cr       CC (N=3)    0.61±0.01         0.61±0.05         1
           CT (N=17)   0.67±0.11         0.67±0.07         0.9330
           TT (N=1)    0.68±.            0.75±.            \-
  AST      CC (N=3)    20±6.24           18.33±3.51        0.4226
           CT (N=17)   20.41±5.79        17.65±4.68        0.0151^\*^
           TT (N=1)    14±.              11±.              \-
  ALT      CC (N=3)    17±7              15±3.61           0.4380
           CT (N=17)   20.29±12.46       16.18±6.85        0.0645
           TT (N=1)    11±.              18±.              \-
  SBP      CC (N=3)    120±3.61          126.67±5.86       0.0377^\*^
           CT (N=17)   122.47±9.68       117±10.6          0.1222
           TT (N=1)    110±.             118±.             \-
  DBP      CC (N=3)    76.33±4.04        76.67±9.24        0.9678
           CT (N=17)   77.29±8.18        72.94±10.18       0.1301
           TT (N=1)    75±.              72±.              \-
  PR       CC (N=3)    84.67±11.93       86.33±10.21       0.6035
           CT (N=17)   77.47±12.1        76.24±9.32        0.7158
           TT (N=1)    79±.              72±.              \-
  RR       CC (N=3)    1.11±0.02         1.14±0.04         0.2222
           CT (N=17)   1.2±0.22          1.18±0.06         0.7960
           TT (N=1)    1.26±.            1.26±.            \-
  -------- ----------- ----------------- ----------------- ---------------

GNB3, G protein beta 3; BW, body weight; BMI, body mass index; RMR, resting metabolic rate; WC, waist circumference; WHR, waist hip ratio; BF%, percentage of body fat; BFM, body fat mass; FI, food intake; BBT, basal body temperature; KOQOL, Korean obesity quality of life; BST, blood sugar test; TG, triglyceride; HDL, high density lipoprotein; T-Chol, total cholesterol; BUN, blood urine nitrogen; Cr, creatinine; AST, aspartate aminotransferase; ALT, aminotransferase; SBP, systolic blood pressure; DBP, diastolic blood pressure; PR, pulse rate; RR, RR interval.

^1)^ *p*-value derived from paired *t*-test between pre and post.

^\*^*p*\<0.05.

### Beta 3 adrenergic receptor

Of the 21 subjects, 15 were Trp64/Trp type without mutation, five were Trp64/Arg type with heterogenic mutation, and one was Arg64/Arg type with homogenous mutation. KOQOL was associated with significant improvement of obesity in both Trp64/Arg and Trp64/Trp types (*p*=0.0090 and *p*=0.0096, respectively), while blood sugar test (BST) was significantly reduced (*p*=0.0375) in the Trp64/Arg type. However, there was no significant difference in the Trp64/Trp type. AST was significantly reduced (*p*=0.0280) in the Trp64/Trp type, while there was no significant change in the Trp64/Arg type ([Table 8](#T008){ref-type="table"}).

###### 

Changes of parameters after intervention by ADRB3 genotype in Korean red ginseng group

  -------- ------------------ ----------------- ----------------- ---------------
           Genotype           Pre               Post              *p*-value^1)^
                                                                  
  BW       Arg64/Arg (N=1)    85.9±.            81.2±.            \-
           Trp64/Arg (N=5)    73.54±12.46       72.94±11.42       0.3062
           Trp64/Trp (N=15)   73.35±7.5         72.91±7.28        0.2843
  BMI      Arg64/Arg (N=1)    27.1±.            25.6±.            \-
           Trp64/Arg (N=5)    29.54±4           29.32±3.73        0.3188
           Trp64/Trp (N=15)   28.58±2.3         28.36±2.28        0.2099
  RMR      Arg64/Arg (N=1)    1830±.            2130±.            \-
           Trp64/Arg (N=5)    1,578±253.81      1,696±206.95      0.2009
           Trp64/Trp (N=15)   1,637.33±214.99   1,649.33±236.75   0.8713
  WC       Arg64/Arg (N=1)    101±.             96.5±.            \-
           Trp64/Arg (N=5)    94.96±9.94        95.54±9.41        0.2871
           Trp64/Trp (N=15)   95.47±6.68        94.37±5.29        0.2058
  WHR      Arg64/Arg (N=1)    0.81±.            0.81±.            \-
           Trp64/Arg (N=5)    0.94±0.03         0.94±0.03         0.0705
           Trp64/Trp (N=15)   0.92±0.04         0.93±0.04         0.0552
  BF%      Arg64/Arg (N=1)    42.1±.            40.3±.            \-
           Trp64/Arg (N=5)    39.14±5.05        39.44±5.96        0.7095
           Trp64/Trp (N=15)   39.71±4.69        39.58±4.37        0.768
  BFM      Arg64/Arg (N=1)    36.1±.            32.7±.            \-
           Trp64/Arg (N=5)    29±7.57           28.96±7.48        0.9498
           Trp64/Trp (N=15)   29.28±5.76        28.93±5.44        0.3517
  FI       Arg64/Arg (N=1)    2077±.            1013±.            \-
           Trp64/Arg (N=5)    1,948.4±590.68    1,578.8±307.86    0.1831
           Trp64/Trp (N=15)   1,784.47±659.87   1,464.07±373.8    0.0985
  BBT      Arg64/Arg (N=1)    36.6±.            36±.              \-
           Trp64/Arg (N=5)    36.66±0.56        36.56±0.35        0.7654
           Trp64/Trp (N=15)   36.59±0.34        36.47±0.28        0.2969
  KOQOL    Arg64/Arg (N=1)    34±.              30±.              \-
           Trp64/Arg (N=5)    40.2±5.63         34.2±2.86         0.009^\*^
           Trp64/Trp (N=15)   39±6              33.73±9.58        0.0096^\*^
  BST      Arg64/Arg (N=1)    117±.             91±.              \-
           Trp64/Arg (N=5)    112.4±10.64       100.2±7.46        0.0375^\*^
           Trp64/Trp (N=15)   103.53±11.44      99.27±13.99       0.4081
  TG       Arg64/Arg (N=1)    99±.              65±.              \-
           Trp64/Arg (N=5)    131.2±26.26       150±116.57        0.7338
           Trp64/Trp (N=15)   108±51.56         97.2±63.66        0.4948
  HDL      Arg64/Arg (N=1)    53±.              50±.              \-
           Trp64/Arg (N=5)    45±6.48           44.4±9.15         0.7664
           Trp64/Trp (N=15)   56.47±10.57       58.2±11           0.4309
  T-Chol   Arg64/Arg (N=1)    179±.             156±.             \-
           Trp64/Arg (N=5)    208±36.41         197.8±35.54       0.2369
           Trp64/Trp (N=15)   183.73±36.22      193.4±58.06       0.3281
  BUN      Arg64/Arg (N=1)    10.5±.            7.7±.             \-
           Trp64/Arg (N=5)    13.12±2.47        13.64±3.79        0.6922
           Trp64/Trp (N=15)   12.51±3.59        12.69±2.83        0.8353
  Cr       Arg64/Arg (N=1)    0.56±.            0.55±.            \-
           Trp64/Arg (N=5)    0.67±0.08         0.68±0.06         0.7449
           Trp64/Trp (N=15)   0.66±0.11         0.67±0.07         0.7736
  AST      Arg64/Arg (N=1)    15±.              17±.              \-
           Trp64/Arg (N=5)    25.4±5.86         19.6±1.95         0.0594
           Trp64/Trp (N=15)   18.6±4.75         16.73±5.16        0.028\*
  ALT      Arg64/Arg (N=1)    17±.              21±.              \-
           Trp64/Arg (N=5)    28.4±13.15        20.8±3.27         0.1809
           Trp64/Trp (N=15)   16.53±10.21       14.2±6.28         0.2274
  SBP      Arg64/Arg (N=1)    124±.             112±.             \-
           Trp64/Arg (N=5)    121±8.31          120.2±11.84       0.9084
           Trp64/Trp (N=15)   121.53±9.98       118.27±10.31      0.3701
  DBP      Arg64/Arg (N=1)    76±.              57±.              \-
           Trp64/Arg (N=5)    75.6±7.64         69.2±6.72         0.3228
           Trp64/Trp (N=15)   77.6±7.84         75.93±9.38        0.5324
  PR       Arg64/Arg (N=1)    72±.              92±.              \-
           Trp64/Arg (N=5)    82.2±16.57        73.2±6.53         0.3268
           Trp64/Trp (N=15)   77.8±10.5         77.93±10.05       0.9532
  RR       Arg64/Arg (N=1)    1.07±.            1.13±.            \-
           Trp64/Arg (N=5)    1.11±0.04         1.17±0.07         0.2235
           Trp64/Trp (N=15)   1.23±0.23         1.18±0.06         0.5531
  -------- ------------------ ----------------- ----------------- ---------------

ADRB3, beta 3 adrenergic receptor; BW, body weight; BMI, body mass index; RMR, resting metabolic rate; WC, waist circumference; WHR, waist hip ratio; BF%, percentage of body fat; BFM, body fat mass; FI, food intake; BBT, basal body temperature; KOQOL, Korean obesity quality of life; BST, blood sugar test; TG, triglyceride; HDL, high density lipoprotein; T-Chol, total cholesterol; BUN, blood urine nitrogen; Cr, creatinine; AST, aspartate aminotransferase; ALT, aminotransferase; SBP, systolic blood pressure; DBP, diastolic blood pressure; PR, pulse rate; RR, RR interval.

^1)^ *p*-value derived from paired *t*-test between pre and post.

^\*^ *p*\<0.05.

### Angiotensin I converting enzyme

Seven subjects were II type without mutation of the 21 subjects, nine were ID type with heterogenic mutation and five were DD type with homogenous mutation. KOQOL for the DD type showed statistically significant effects on obesity improvement (*p*=0.0030), while in the II and ID types, only a decreasing tendency was detected. BST and AST were significantly reduced in II type (*p*=0.0227 and *p*=0.0218, respectively), while in the ID and DD types, only a decreasing tendency was detected ([Table 9](#T009){ref-type="table"}).

###### 

Changes of parameters after intervention by ACE genotype in Korean red ginseng group

  -------- ---------- ----------------- ----------------- ---------------
           Genotype   Pre               Post              *p*-value^1)^
                                                          
  BW       DD (N=5)   71.46±10.75       70.46±9.02        0.3518
           ID (N=9)   74.78±7.11        74.12±7.18        0.3196
           II (N=7)   74.8±10.39        74.31±9.47        0.3292
  BMI      DD (N=5)   28.36±2.07        28.06±2.33        0.3965
           ID (N=9)   29.23±2.17        29±2.33           0.3676
           II (N=7)   28.37±3.78        28.04±3.43        0.1689
  RMR      DD (N=5)   1,518±272.34      1,646±306.48      0.2096
           ID (N=9)   1,611.11±231.32   1,683.33±221.47   0.4083
           II (N=7)   1,741.43±116.54   1,710±256.12      0.8039
  WC       DD (N=5)   91.7±6.08         91.46±4.35        0.8334
           ID (N=9)   96.61±7.29        95.16±6.55        0.2101
           II (N=7)   97.11±7.92        96.59±6.53        0.6753
  WHR      DD (N=5)   0.91±0.06         0.92±0.06         0.0705
           ID (N=9)   0.93±0.04         0.93±0.05         0.1950
           II (N=7)   0.91±0.04         0.92±0.0          0.1723
  BF%      DD (N=5)   39.5±3.57         39.32±4.57        0.8135
           ID (N=9)   40.37±5.5         40.34±5.13        0.9733
           II (N=7)   38.94±4.41        38.79±4.22        0.7797
  BFM      DD (N=5)   28.28±5.3         27.64±4.41        0.4909
           ID (N=9)   30.33±6.3         30.07±6.09        0.6142
           II (N=7)   29.41±7.02        28.96±6.56        0.3991
  FI       DD (N=5)   1,699.6±433.39    1,334.2±441.3     0.2112
           ID (N=9)   1,838.44±715.71   1,400.33±387.43   0.1333
           II (N=7)   1,934.57±663.61   1,656.29±202.16   0.2695
  BBT      DD (N=5)   36.56±0.32        36.46±0.43        0.7594
           ID (N=9)   36.57±0.33        36.47±0.3         0.5403
           II (N=7)   36.69±0.5         36.49±0.26        0.2023
  KOQOL    DD (N=5)   36±2.83           30.4±4.1          0.0030^\*^
           ID (N=9)   39±6.69           34.44±9.25        0.0674
           II (N=7)   41.29±5.65        35±9.22           0.0641
  BST      DD (N=5)   107.4±10.01       102.4±9.86        0.5851
           ID (N=9)   106.11±13.06      101.56±11.9       0.5496
           II (N=7)   105.71±12.42      93.57±14.08         0.0227\*
  TG       DD (N=5)   111.2±41.34       142.2±120.91      0.5608
           ID (N=9)   108±45.84         93.89±77.14       0.5404
           II (N=7)   121±54.58         102.43±39.92      0.3742
  HDL      DD (N=5)   53±11.66          50.8±10.85        0.3694
           ID (N=9)   55.22±9.68        58.78±13.62       0.2638
           II (N=7)   51.86±12.14       51.71±9.34        0.9526
  T-Chol   DD (N=5)   191.4±32.24       182±38.23         0.2555
           ID (N=9)   188.44±41.36      207.44±71.16      0.2441
           II (N=7)   188.86±36.77      181.29±25.59      0.1898
  BUN      DD (N=5)   10.98±2.96        10.36±1.78        0.5931
           ID (N=9)   11.58±1.95        11.94±2.18        0.7454
           II (N=7)   14.96±3.74        15.27±3.4         0.8129
  Cr       DD (N=5)   0.67±0.09         0.67±0.09         1.0000
           ID (N=9)   0.62±0.08         0.64±0.06         0.2148
           II (N=7)   0.71±0.11         0.69±0.07         0.5296
  AST      DD (N=5)   23.8±6.53         17.6±3.97         0.0666
           ID (N=9)   17.44±3.47        17.11±4.88        0.5943
           II (N=7)   20.71±6.47        17.71±5.22          0.0218\*
  ALT      DD (N=5)   27±14.2           19.6±5.03         0.1989
           ID (N=9)   14±4.97           14.22±6.63        0.8695
           II (N=7)   20.86±13.63       16±6.3            0.2162
  SBP      DD (N=5)   121.2±7.79        120.4±8.26        0.8620
           ID (N=9)   121.44±12.24      115.22±8.84       0.1947
           II (N=7)   121.86±6.28       121.14±13.18      0.9131
  DBP      DD (N=5)   77.6±5.03         71.4±8.32         0.2314
           ID (N=9)   77.44±8.82        73.11±8.55        0.2146
           II (N=7)   76.14±7.95        75.29±12.63       0.8768
  PR       DD (N=5)   79±16.09          83.4±8.59         0.5296
           ID (N=9)   72.44±7.06        73.22±8.32        0.8271
           II (N=7)   86.14±9.87        78.71±10.73       0.1764
  RR       DD (N=5)   1.14±0.06         1.18±0.07         0.1879
           ID (N=9)   1.16±0.05         1.16±0.07         0.3559
           II (N=7)   1.26±0.35         1.19±0.05         0.6647
  -------- ---------- ----------------- ----------------- ---------------

ACE, angiotensin I converting enzyme; BW, body weight; BMI, body mass index; RMR, resting metabolic rate; WC, waist circumference; WHR, waist hip ratio; BF%, percentage of body fat; BFM, body fat mass; FI, food intake; BBT, basal body temperature; KOQOL, Korean obesity quality of life; BST, blood sugar test; TG, triglyceride; HDL, high density lipoprotein; T-Chol, total cholesterol; BUN, blood urine nitrogen; Cr, creatinine; AST, aspartate aminotransferase; ALT, aminotransferase; SBP, systolic blood pressure; DBP, diastolic blood pressure; PR, pulse rate; RR, RR interval.

^1)^ *p*-value derived from paired *t*-test between pre and post.

^\*^ *p*\<0.05.

Safety evaluation of Korean red ginseng
---------------------------------------

For the safety evaluation of KRG, blood tests on liver function and renal function were carried out before and after drug administration, and BP and heart rate were measured in every visit. In the blood tests for the evaluation of the liver and renal functions before and after KRG, AST was statistically significantly reduced (*p*=0.0033), while there was no significant difference in the rest, including BUN, creatinine, and ALT. Also, in the comparison with the placebo group, there was no significant difference. In the comparison of BP and heart rate before and after KRG administration, there was no significant difference between KRG group and placebo group ([Table 10](#T010){ref-type="table"}). To check adverse event of KRG intake, an interview-style medical examination was carried out every second week. During the 8 week study, there were no adverse events in the KRG and placebo groups.

###### 

Changes for safety outcome variables

  ------------------- ------------- -------------- --------------- ----- ------------- ---------------
  Variables           Red ginseng   Placebo                                            
                                                                                       
                      No.           Mean±SD        *p*-value^1)^   No.   Mean±SD       *p*-value^2)^
                                                                                       
  BUN at baseline     22            12.65±3.2                      23    12.07±2.96    0.5273
  Week 8 - baseline   22              0.29±3.04    0.6627          23    1.79±3.49     0.1319
  Cr at baseline      22            0.66±0.1                       23    0.66±0.09     0.9218
  Week 8 - baseline   22                  0±0.05   0.7217          23    -0.02±0.05    0.1444
  AST at baseline     22            20.05±5.58                     23    25.65±12.07   0.0526
  Week 8 - baseline   22            -2.68±3.8        0.0033^\*^    23    -3.74±9.1     0.612
  ALT at baseline     22            19.14±11.37                    23    29.7±16.17    0.0154^\*^
  Week 8 - baseline   22            -3.27±7.92     0.0663          23    -5.3±8.42     0.4097
  SBP at baseline     22            122.18±9.46                    23    123.61±9.91   0.6241
  Week 8 - baseline   22            -2.86±13.09    0.3164          23    -1.43±10.57   0.6883
  DBP at baseline     22            77.23±7.32                     23    77.61±7.4     0.8629
  Week 8 - baseline   22            -3.86±10.75    0.1068          23    -1.13±6.92    0.3142
  PR at baseline      22            78.27±11.55                    23    74.43±6.69    0.1841
  Week 8 - baseline   22            -1.05±12.2     0.6919          23    -2.13±9.36    0.7388
  ------------------- ------------- -------------- --------------- ----- ------------- ---------------

BUN, blood urine nitrogen; Cr, creatinine; AST, aspartate aminotransferase; ALT, aminotransferase; SBP, systolic blood pressure; DBP, diastolic blood pressure; PR, pulse rate.

^1)^ *p*-value derived from paired *t*-test between pre and post.

^2)^ *p*-value derived from Student's *t*-test between red ginseng group and placebo group.

^\*^*p*\<0.05.

Confirmation of the appropriateness of blind test for the subjects
------------------------------------------------------------------

To check the appropriateness of the blinding for the subjects after the clinical trials, a self-questionnaire was distributed to inquire on subjects' perceptions of whether they received KRG or placebo. As a result, 18 (81.8%) of the 22 subjects who completed the test and who had been assigned to KRG group responded that they thought that they had taken the KRG, while four (18.2%) responded that they thought that they had taken the placebo. Of the 23 subjects who had completed the test and who had been assigned to placebo group, 16 (69.6%) responded that they had taken the KRG while seven (30.4%) responded that they thought that they had taken placebo.

DISCUSSION
==========

The effects of KRG on the improvements of obesity and abnormal metabolism have been proven in several studies. KRG extract injected in mice with obesity caused by high fat diet prevented weight increase and increases in and subcutaneous fat and adipocyte size [@B015]. KRG saponin administered to mice with obesity caused by high fat diet reduced body weight, diet intake, body fat, and serum leptin density and controlled expression of neuropeptide Y in the hypothalamus [@B010]. Clinical studies have reported administration of KRG complex significantly influences weight and body fat losses compared to placebo and increased beta-adrenergic activity [@B016], that complex exercises and the injection of KRG complex reduces the percentage of body fat, weight, and serum lipid profile of obese women in their 20s [@B014],[@B016], and that the risk factors of obesity, hypertension, and arteriosclerosis are restrained in people who consume ginseng for a long time (about 4-5 yr) compared to those who had not [@B017].

In this study, before and after administration, two subjects in the KRG group (9.09%) displayed \>5% weight loss, while none of those in the placebo group displayed comparable weight loss. However, the difference was not statistically significant. In the KRG group, when obesity indices before and after drug administration were compared, weight, BMI, WHR, FI, KOQOL, and AST showed statistically significant decreases. However, except for KOQOL, there was no significant difference from those of the placebo group. Thus, the effects of KRG on the improvement of obesity were confirmed to some extent, although distinct effects on the improvement compared to placebo group were not confirmed.

The KOQOL evaluation is a method of evaluating the quality of life through a self-answered questionnaire consisting of 15 questions in six areas regarding mental and social health, physical health, job work and housekeeping, daily life, sexual relations, and food, which is known to be very reliable and relevant [@B014]. Unlike other indices of anthropometric assessment and blood test, since this quality of life evaluation is subjective, bias by placebo effects is very likely to occur. However, in the examination of the appropriateness of the blinding on the subject carried out after the test period in this study, it turned out to be maintained relatively well. Therefore, it can be interpreted that KRG is more effective for improving the secondary issues of the quality of life derived from obesity rather than has direct effects on the obesity-related anthropometric assessment and blood test indices.

However, existing studies on obesity related to KRG report significant effects on anthropometric assessment and blood test indices also. There are several reasons for the contradictory results in this study. The KRG powder capsule provided in this study was 500 mg, so consumption of a dose of 6 g required 12 capsules to be taken. This may have lowered compliance, lessening the effects of KRG on the improvement of obesity. However, as leftover drugs had to be returned, compliance could be checked. The compliance rate exceeded 80%. However, drug return was voluntary, so the actual compliance rate is unclear.

In the GNB3 gene, C825T gene polymorphism is related to obesity. The T allele of the GNB3 gene is associated with increased intra-cellular signal transduction and renin activity and has been implicated in diseases such as arterial hypertension and obesity [@B018]. Possession of the T allele increases the heart's stroke volume and renal flow, which greatly increases the prevalence rate of hypertension and cardiovascular diseases [@B019]. BMI 25 is 2 to 3 times higher in people with T allele than in the C allele [@B017]. Domestic studies include reports of significant differences by GNB3 gene polymorphism in the improvements of Korean middle-aged women's weight, triglycerides, HDL, insulin and HOMA index by aerobic exercises [@B020]. In contrast, in one study, GNB3 polymorphism did not have anything significant to do with the BP, obesity indices, serum lipid profile, and obesity-related protein for Korean middle-aged women [@B021].

This study confirmed that the BMI, BF%, and systolic BP pressure of subjects with GNB3 gene mutation (CT+TT) was significantly higher than that without the mutation (CC). This result is consistent with previous studies, in which the T allele increased the risk of obesity [@B017]-[@B019]. In the CT type with heterogenous mutation, systolic BP was significantly reduced by KRG, while in the mutation-free CC type there was no significant change. Moreover, in the latter, compared to CT type, although food intake was much more significantly reduced, there was a more significant change in the CT type for the above two items. Thus, the effects of KRG on the improvement of obesity were more pronounced for those whose energy metabolism was reduced by the presence of a GNB3 gene mutation.

The ADRB3 gene is expressed in fat tissues, which, in humans, mainly exists in brown fat tissues and in white adipose tissue after growth [@B022]. Its function has not been clearly proven yet. However, it is known to activate heat generation in the brown adipose tissue and to stimulate lipolysis in the white adipose tissue as a G protein-associated receptor, and this energy controlling function is known to be related to obesity [@B023],[@B024]. If ADRB3 gene mutation is homogenous, there is low basal metabolism and high BMI, and it accelerates the age of onset of diabetes [@B025]. But, the phenotype of obesity differs depending on the race. In a study on Finnish men [@B026] and French men [@B027] ADRB3 gene polymorphism produced a significant increase of the risk of obesity or metabolic diseases in heterogeneous mutation as well as homogenous mutation. However, in a study on Mexican Americans [@B028], only homogenous mutation was associated with significantly increased risks of obesity or metabolic diseases. In Korea, a comparison of middle-aged women's body constitution and serum lipid profile density after exercise treatment by ADRB3 gene polymorphism reported no significant difference [@B029], and in a comparative study on reactions to Orlistat drug administration by ADRB3 gene polymorphism mutation, weight, WC, and BMI tended to be reduced more than in non-mutation group, although the difference was statistically insiginificant [@B030].

In this study, the group with heterogeneous mutation of the ADRB3 gene (Trp64/Arg) had significantly lower HDL than that without mutation (Trp64/Trp), so the risk of metabolic diseases was increased when there was a gene mutation. However, the difference by genotype was not confirmed in the rest of the obesity indices. Since other related studies [@B029],[@B030] have reported a lack of correlation between the mutation of ADRB3 gene and obesity response, it is conceivable that the association of ADRB3 gene polymorphism with obesity is weaker in Koreans than other races. Also, in this study, since there were only five subjects with the Arg64/Arg type of homogenous mutation, the difference by gene polymorphism might not been apparent in the obesity indices.

The ACE gene product is secreted from endotheliocytes in the kidney. It converts angiotensin I to angiotensin II, and reduces the vasodilator bradykinin, which is related to the density of ACE enzyme that plays an important role in controlling of the homeostasis of circulatory functions. If serum ACE level increases, blood vessel is contracted. And that elevates BP and the risks of myocardial infraction. Consequently coronary artery disease increase. If the ACE gene is deficient, the density of serum ACE level increases. It has been reported that people with II gene type display lower BP and higher endurance than people with DD gene type did, while the risk of cardiovascular diseases of those with DD gene type is increased [@B031]. Also, a study on type 2 diabetics in China reported that DD type was associated with higher triglycerides [@B032] and the serum ACE level of obese people was higher than that of those who were not [@B033]. The athletic ability of Koreans with the ACE gene type with the ID or DD mutation tends to be less and they are more likely to be obese [@B034]-[@B037]. This study, unlike existing study results, was not able to confirm the significant relationship between the ACE gene polymorphism and the obesity indices. Since this study set obesity patients as the target of study, already all samples were acquired from an obese subject. Accordingly, it is supposed that there was no difference of phenotype by gene polymorphism. When the effects of KRG on the improvement of obesity were compared to ACE gene polymorphism, there were significant effects on improvement by the evaluation on the KOQOL scale only in the DD type (homogeneous mutation), while a decreasing tendency only was found in the ID type (heterogeneous mutation) and the II type (without mutation). However, in the remainder of the obesity indices, it was not confirmed that the treatment effects of KRG differed depending on gene polymorphism.

The safety of KRG has been documented in a variety of studies. Also, since in this study there was no significant change in the comparison of blood tests (AST, ALT, BUN, and creatinine) before and after KRG administration, and there was no report of special adverse event during the 8-week clinical trials, the safety of the administration of KRG of 18 g a day (three times, 6 g each) for 8 wk could be reconfirmed.

A pharmacogenomic study tries to explain individual differences of drug reactions by genetic differences, of which importance has been relatively recently recognized and a field in which active studies are in progress. Pharmacogenomic studies not only make it more effective individualized custom treatment possible, by understanding the differences of drug reactions according to the genetic characteristics of individuals, but also predict adverse events of the drugs, so that they will be able to used more safely. In addition, such studies can enhance the success rate and shorten the time required through efficient clinical trials in developing new medicines. Also, through pharmacogenomic studies, the mechanisms of onset of some genetic diseases can be understood, so that they can be prevented. This study is also a kind of pharmacogenomic study, which tried to examine the differences of the effects of KRG on the improvement of obesity by gene mutation. This study has not clearly proved the differences in the effects of KRG on the improvement of obesity by gene. However, it has strengths of randomization, double blinding, and placebo control.
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